1. Home
  2. CION vs ACIU Comparison

CION vs ACIU Comparison

Compare CION & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CION Investment Corporation

CION

CION Investment Corporation

HOLD

Current Price

$6.44

Market Cap

304.7M

Sector

Finance

ML Signal

HOLD

Logo AC Immune SA

ACIU

AC Immune SA

HOLD

Current Price

$2.43

Market Cap

244.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CION
ACIU
Founded
2011
2003
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
304.7M
244.3M
IPO Year
2011
2015

Fundamental Metrics

Financial Performance
Metric
CION
ACIU
Price
$6.44
$2.43
Analyst Decision
Sell
Strong Buy
Analyst Count
1
2
Target Price
$7.00
$10.00
AVG Volume (30 Days)
632.2K
269.2K
Earning Date
05-07-2026
05-12-2026
Dividend Yield
15.96%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$706.75
Revenue Next Year
N/A
$321.13
P/E Ratio
$17.55
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.97
$2.00
52 Week High
$10.93
$4.00

Technical Indicators

Market Signals
Indicator
CION
ACIU
Relative Strength Index (RSI) 47.66 45.44
Support Level $5.97 $2.15
Resistance Level $6.60 $2.66
Average True Range (ATR) 0.22 0.16
MACD 0.02 0.02
Stochastic Oscillator 73.90 51.45

Price Performance

Historical Comparison
CION
ACIU

About CION CION Investment Corporation

CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Companies portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.

About ACIU AC Immune SA

AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Share on Social Networks: